The PE Ratio as of September 2024 (TTM) for Keros Therapeutics, Inc. (KROS) is -10.24

According to Keros Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.24. This represents a change of 21.95% compared to the average of -8.40 of the last 4 quarters.

Keros Therapeutics, Inc. (KROS) Historical PE Ratio (quarterly & annually)

How has KROS PE Ratio performed in the past?

The mean historical PE Ratio of Keros Therapeutics, Inc. over the last ten years is -35.77. The current -10.24 PE Ratio has changed 2.76% with respect to the historical average. Over the past ten years (40 quarters), KROS's PE Ratio was at its highest in in the September 2023 quarter at -6.00. The PE Ratio was at its lowest in in the December 2021 quarter at -49.39.

Keros Therapeutics, Inc. (KROS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Keros Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Keros Therapeutics, Inc. (KROS) Average PE Ratio

How has KROS PE Ratio performed in the past?

The current PE Ratio of Keros Therapeutics, Inc. (KROS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Keros Therapeutics, Inc. (KROS) PE Ratio vs. Peers

How is KROS’s PE Ratio compared to its peers?

Keros Therapeutics, Inc.’s PE Ratio is greater than IDEAYA Biosciences, Inc. (-18.36), less than AnaptysBio, Inc. (-5.77), less than MeiraGTx Holdings plc (-2.68), less than Homology Medicines, Inc. (-0.01), greater than Janux Therapeutics, Inc. (-51.01), less than Fennec Pharmaceuticals Inc. (54.24), greater than Edgewise Therapeutics, Inc. (-14.14), less than Harmony Biosciences Holdings, Inc. (17.58), less than Aerovate Therapeutics, Inc. (-0.62), less than Syndax Pharmaceuticals, Inc. (-6.17), less than Mineralys Therapeutics, Inc. (-4.63), less than Replimune Group, Inc. (-3.26), less than Erasca, Inc. (-3.94), less than Century Therapeutics, Inc. (-0.91), less than NGM Biopharmaceuticals, Inc. (-0.91), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Surrozen, Inc. (-0.55), less than Bolt Biotherapeutics, Inc. (-0.37), less than Larimar Therapeutics, Inc. (-8.80), less than Kezar Life Sciences, Inc. (-0.41),

Build a custom stock screener for Keros Therapeutics, Inc. (KROS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Keros Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Keros Therapeutics, Inc. (KROS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Keros Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.